AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
Log in

NYSEAMERICAN:ISRIsoRay Stock Price, Forecast & News

$0.70
0.00 (0.00 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.70
Now: $0.70
$0.72
50-Day Range N/A
52-Week Range
$0.29
Now: $0.70
$1.06
Volume456,980 shs
Average Volume580,069 shs
Market Capitalization$47.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.
Read More
IsoRay logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ISR
Previous SymbolNYSEMKT:ISR
CUSIPN/A
Phone+1-509-3751202

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees38
Market Cap$47.56 million
Next Earnings Date9/22/2020 (Estimated)
OptionableNot Optionable

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.

IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of IsoRay?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IsoRay.

When is IsoRay's next earnings date?

IsoRay is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020. View our earnings forecast for IsoRay.

How were IsoRay's earnings last quarter?

IsoRay, Inc. (NYSEAMERICAN:ISR) posted its quarterly earnings data on Tuesday, May, 12th. The healthcare company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). The healthcare company earned $2.88 million during the quarter, compared to analysts' expectations of $2.76 million. View IsoRay's earnings history.

What price target have analysts set for ISR?

3 analysts have issued 12-month price targets for IsoRay's stock. Their forecasts range from $1.25 to $1.75. On average, they anticipate IsoRay's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 113.4% from the stock's current price. View analysts' price targets for IsoRay.

Has IsoRay been receiving favorable news coverage?

Media stories about ISR stock have trended positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IsoRay earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the healthcare company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutIsoRay.

Who are some of IsoRay's key competitors?

What other stocks do shareholders of IsoRay own?

Who are IsoRay's key executives?

IsoRay's management team includes the following people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 57)
  • Mr. Michael L. Krachon, VP of Sales & Marketing (Age 48)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 53)
  • Mr. Jonathan R. Hunt, Co-Principal Financial Officer (Age 52)
  • Mr. Mark J. Austin CPA, Controller & Co-Principal Financial Officer (Age 32)

What is IsoRay's stock symbol?

IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Who are IsoRay's major shareholders?

IsoRay's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.71%), EAM Investors LLC (1.60%), Highland Private Wealth Management (0.80%), Acadian Asset Management LLC (0.19%) and Starfire Investment Advisers Inc. (0.10%). Company insiders that own IsoRay stock include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh. View institutional ownership trends for IsoRay.

Which major investors are buying IsoRay stock?

ISR stock was purchased by a variety of institutional investors in the last quarter, including EAM Investors LLC, Highland Private Wealth Management, Acadian Asset Management LLC, BlackRock Inc., and Starfire Investment Advisers Inc.. Company insiders that have bought IsoRay stock in the last two years include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, and William Cavanagh. View insider buying and selling activity for IsoRay.

How do I buy shares of IsoRay?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IsoRay's stock price today?

One share of ISR stock can currently be purchased for approximately $0.70.

How big of a company is IsoRay?

IsoRay has a market capitalization of $47.56 million. IsoRay employs 38 workers across the globe.

What is IsoRay's official website?

The official website for IsoRay is isoray.com.

How can I contact IsoRay?

IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.